Restoration of Central Vision With the PRIMA System in Patients With Atrophic Age-Related Macular Degeneration
Summary
The PRIMAvera pivotal clinical trial of Science Corporation's PRIMA retinal BCI implant in 38 patients with geographic atrophy (advanced dry AMD) — the study whose results were published in NEJM October 2025 showing 80% of patients restored functional visual acuity. Results demonstrated restoration of the ability to read letters, numbers, and words; meaningful improvement in visual acuity; and maintenance of simultaneous peripheral natural vision alongside central prosthetic vision. Science has submitted CE mark application and is targeting European commercial launch as the first BCI company to reach the market.
Why it matters
PRIMAvera is the pivotal trial that turned Science Corporation from a clinical-stage company into a pre-commercial one. With 80% of 38 patients reading letters from a 2mm retinal chip, this trial will be cited as the proof point for sensory BCI every time the field is discussed for the next decade. CE mark approval converts this clinical proof into the world's first commercially available BCI sensory restoration product.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial